| Field | Specification |
|---|---|
| Target | |
| Alternative names | Aging associated gene 8 protein; Aging-associated gene 8 protein; AL024364; hSigmaR1; mSigmaR1; opioid receptor, sigma 1; opioid receptor, sigma 1 isoform 1; RP23 167I12.6; SGMR1_HUMAN; SIG 1R; SIG-1R; Sigma 1-type opioid receptor; Sigma non-opioid intracellular receptor 1; sigma1 receptor; Sigma1-receptor; Sigma1R; Sigmar1; SR BP; SR-BP; SR31747 binding protein; SR31747-binding protein; SRBP |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | Recombinant Human Sigma non-opioid intracellular receptor 1 protein (112-169AA) |
| Conjugate | |
| Source | This product is a polyclonal antibody purified from rabbit antiserum. |
| Purification | |
| Form | Liquid |
| Storage | |
| Storage buffer | |
| Catalog no. (Mfr.) | |
| Main SKU |
Overview
This polyclonal anti-SIGMAR1 antibody raised in Rabbit, conjugated with Biotin, tested in ELISA. Designed to detect SIGMAR1 in Human for others research.
Key elements and design rationale
- Immunogen: Recombinant Human Sigma non-opioid intracellular receptor 1 protein (112-169AA) — determines epitope; confirm sample prep compatibility.
- Host (Rabbit): Requires anti-rabbit-IgG secondary matching isotype IgG.
- Polyclonal: Multiple epitopes = robust signal; lot-to-lot variability — include controls.
- Isotype (IgG): Match secondary, Protein A/G, and isotype controls to IgG.
- Purification (Protein G purification): Enriches Ig classes; reduces non-specific background.
- Biotin: Streptavidin/avidin amplification; block endogenous biotin in biotin-rich samples.
Biological background
SIGMAR1 (also: Aging associated gene 8 protein, Aging-associated gene 8 protein, AL024364, hSigmaR1, mSigmaR1, opioid receptor, sigma 1, opioid receptor, sigma 1 isoform 1, RP23 167I12.6, SGMR1_HUMAN, SIG 1R, SIG-1R, Sigma 1-type opioid receptor, Sigma non-opioid intracellular receptor 1, sigma1 receptor, Sigma1-receptor, Sigma1R, Sigmar1, SR BP, SR-BP, SR31747 binding protein, SR31747-binding protein, SRBP) — studied in Human systems. Expression, localization, and PTMs vary across cell types and disease states. Consult UniProt, NCBI Gene, and primary literature for current SIGMAR1 annotation relevant to others.
Common research applications
- ELISA: Quantify soluble target; ensure samples within the linear detection range.
Notes for experimental interpretation
- Isotype controls: IgG from Rabbit at equivalent concentration.
- Cross-reactivity: Polyclonal: validate with KO/KD controls.
- Matrix effects: Verify dilution linearity in your sample matrix.
- Reactivity: Confirmed for Human; extrapolation requires validation.
This product is a polyclonal antibody purified from rabbit antiserum.
SIGMAR1 is a protein studied in Human biology. This polyclonal antibody raised in Rabbit detects SIGMAR1 in ELISA applications, IgG isotype.
Reported reactive against Human. Immunogen from Human. Cross-reactivity with untested species requires empirical confirmation.
Reported for ELISA. Optimize dilution/blocking per application. Consult datasheet for working concentrations.
Biotin: streptavidin/avidin amplification. Block endogenous biotin in biotin-rich samples.
(1) Isotype control: IgG from Rabbit; (2) Positive control: lysate/cell line expressing SIGMAR1; (3) Negative control: siRNA KD or KO; (4) Dilution linearity in your sample matrix.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
